Navigation Links
M. D. Anderson examines use of toad venom in cancer treatment
Date:9/24/2009

roved by both institutional review boards. M. D. Anderson and Fudan University Cancer Hospital signed a sister institution agreement in 2003, creating a framework for research, educational and clinical collaboration.

The typical dose of huachansu used in China is approximately 15 milliliters of drug per meter squared of body mass (mL/m2). In the study, 15 patients with stage III or IV hepatocellular (liver) carcinoma, nonsmall cell lung cancer or pancreatic cancer received one of five dose levels ranging from 10 mL/ m2 up to 90 mL/m2 from January 2005 through July 2006. The treatment was repeated daily for 14 days followed by seven days off (one cycle). After two cycles, most patients received other treatments. Quality control methods were put in place to ensure huachansu of a uniform and consistent lot.

While the dose was up to eight times higher than conventional doses used in China, researchers observed only low toxicities or side effects. Eleven (73 percent) patients had no toxicities greater than the lowest grade measured. Importantly, no significant cardiac toxicity was observed and no significant changes in cancer-related symptoms occurred. Of the 15 patients who completed the treatment, six hepatocellular carcinoma patients (40 percent) had stable disease for a median of six months. One patient had a 20 percent reduction in tumor mass that lasted for more than 11 months.

"Even though we saw no complete or partial response (reduction of disease by 30 percent or more) it is encouraging that the cancer did not progress in a large set of the hepatocellular carcinoma patients," says Zhiqiang Meng, principal investigator on the trial and an associate professor and deputy chair of the Department of Integrative Oncology at Fudan University Cancer Hospital, "Previous observations from studies conducted in China have shown that huachansu can inhibit tumor cell growth and improve immunologic function3. These findings, coupled with that kno
'/>"/>

Contact: Lindsay Anderson
lindsay.anderson@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. M.D. Anderson-led team reports possible key to autoimmune disease
2. UCI Medical Affiliates Inc. Opens a New Doctors Care Center in Anderson
3. M. D. Anderson-Prevention poll finds women can do more to prevent cancer...but arent
4. M. D. Anderson-Prevention poll finds women can do more to prevent cancer ... but arent
5. M. D. Anderson researchers identify tumor-suppressor gene for lung cancer
6. SEIU Endorses Anderson, Perea, and Perea in Fresno
7. M. D. Anderson research links diet, gardening and lung cancer risk
8. CyberKnife Centers of Miami, Palm Beach and Tampa Invited to Join M.D. Anderson Cancer Center Study
9. Naviscan PET Systems to Place High-Resolution PET Scanner at M. D. Anderson Cancer Center
10. M. D. Anderson nurses find empowerment in PACTs
11. M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Blacks, other minorities might not gain full benefit from ... -- Human embryonic stem cell lines currently used for ... finds. , That could mean that non-whites will ... that research down the line, experts say. , Blacks ... most widely used stem cell lines studied showed any ...
(Date:12/16/2009)... (Nasdaq: MDRX ) announced today that it ... and six months ended November 30, 2009 before ... 2010. Allscripts management will host a conference call ... other information at 8:30 AM Eastern Standard Time ... ) ,, Allscripts fiscal second quarter earnings will ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 As a result of ... a new peer reviewed cancer research program is included ... ,, This new cancer research program will research ... the breast, prostate, lung and ovarian cancer research programs ... Command. ,, The $15 million in funding ...
(Date:12/16/2009)... that increase susceptibility to disease , , WEDNESDAY, Dec. ... increased susceptibility to leprosy have been identified by ... who analyzed more than 10,000 DNA samples from ... their discovery highlights the important role that the ... leprosy. , "Though leprosy is not common, the ...
(Date:12/16/2009)... health and environmental concerns about the emerging nanotechnology industry, ... behavior of nanoparticles in municipal sewage treatment plants ... published in ACS, journal Environmental Science & Technology ... Ecology and Hydrology and colleagues note that experts predict ... less than 1/1000th the width of a human hair ...
Breaking Medicine News(10 mins):Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Leprosy Genes Identified 2Health News:Behavior modification could ease concerns about nanoparticles 2
... Jack Mackenroth to debut signature campaign scarf at ... NEW YORK, Nov. 7 Jack Mackenroth, from ... debuting an HIV and AIDS,education campaign called Living ... Men,s Health Crisis Fashion Forward event. At Fashion ...
... combine efforts to simplify claims and transaction ... Nov. 10 In order,to provide solutions ... for healthcare companies, Axway, recognized leader of ... quality and compliance,solutions have formed a strategic ...
... via Google Earth and,Compatibility with Polar,s Range of ... N.Y., Nov. 10 Polar (http://www.polarusa.com ),the ... technology,today introduced the RS800CX, the most advanced and ... the growing,multisport market., The RS800CX offers athletes ...
... Revenue and Gross Profit Increase, LOVELAND, Colo., ... today reported financial results for its third quarter ... Heska Corporation ("Heska" or the "Company") generated ... an increase of 21% from the,prior year period., ...
... 3 Clinical Trial For Duska,s ATPace In Planning ... Nov. 10 /PRNewswire-FirstCall/,-- Duska Therapeutics, Inc., (OTC Bulletin ... they have entered into a,preliminary agreement to collaborate ... Duska,s planned pivotal Phase 3 clinical trial in,paroxysmal ...
... Montreal Heart Institute Research,Centre Director Dr. ... trial demonstrating that VIA-2291, an investigational drug ... production,of leukotrienes, proposed mediators of vascular inflammation, ... well-tolerated with no serious,adverse events attributed to ...
Other Medicine News:Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 2Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 3Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 4Health News:Axway and Edifecs Form Strategic Partnership to Benefit Healthcare Payors 2Health News:Axway and Edifecs Form Strategic Partnership to Benefit Healthcare Payors 3Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 2Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 3Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 4Health News:Heska Announces Q3 2008 Results 2Health News:Heska Announces Q3 2008 Results 3Health News:Heska Announces Q3 2008 Results 4Health News:Heska Announces Q3 2008 Results 5Health News:Heska Announces Q3 2008 Results 6Health News:Heska Announces Q3 2008 Results 7Health News:Heska Announces Q3 2008 Results 8Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 2Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 3Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 4Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 5Health News:The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease 2Health News:The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease 3
(Date:12/16/2009)... Ill., Dec. 16 Hospira, Inc. (NYSE: ... medication delivery company, today announced that it will host ... 2009 results and projections for 2010 on Thursday, Feb. ... company will release its fourth-quarter and full-year 2009 results ... and the conference call. ,, A live webcast of ...
(Date:12/16/2009)... International, well-known,scientific experts were ... (80 mg/day),data presented as "extremely promising."[1] ... and clinicians critically reviewed these data.,These ... generic lipid-modifying,treatments, fenofibrate and bezafibrate, in ... in patients with metabolic syndrome,and type ...
(Date:12/16/2009)... -- Verathon®, maker of BladderScan® bladder volume ... bladder volume ultrasound is now included in ... Prevention of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... early November 2009, replace the previous guidelines ... guidelines are located on the Web at: ...
Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 1AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 2AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 3AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 4Mach One Corporation Developing a Nasal Hand Carried Product as Solution to Swine Flu 28H1N1 29 Virus 12476 1Mach One Corporation Developing a Nasal Hand Carried Product as Solution to Swine Flu 28H1N1 29 Virus 12476 2Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 1Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 2Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 3
... LATHAM, N.Y., Aug. 25 Clinicians from ... Physicians in,Latham have commenced treating cancer patients using ... VAR ), an,advancement that delivers a highly-precise image-guided,intensity-modulated ... RapidArc treatments spare healthy tissue and other ...
... Studies ... Planned, COPENHAGEN, Denmark, ... in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) announced ... and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have worked ...
Other Medicine Technology:Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... & Nephew ECTRA II systems permit the ... tunnel ligament endoscopically, allowing access via two ... minimizing endoscopic lens fogging with good air ... visualization and control. ECTRA knives permit the ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Medicine Products: